Breathe Technologies: Penetrating The Ventilator Market

Breathe Technologies is bringing a bit of disruption to the staid ventilator market: NIOV, a portable ventilator, can help patients breathe easier both inside and outside the hospital. But perhaps because innovation in this field isn’t common, the company is meeting resistance from some payors, most notably the Centers for Medicare and Medicaid Services, which doesn’t see the device as a ventilator but rather another form of oxygen therapy.

Here’s a simple fact about health care: no drug or device will improve a person’s health if he can’t draw a simple breath. Without the ability to draw complete tissue-enriching oxygen to the entire body, an otherwise healthy person is resigned to a life of headaches, fatigue, pain, and loss of cognition skills. Without relief, this shortness of breath – or dyspnea – will continuously pull a person down into a prison of immobility and, eventually, death. A healthy person needs only to spend a short time taking all of his air through a drinking straw to appreciate the awful sensation.

At some point, the downward spiral will land a person in a hospital bed or another clinical setting where a...

More from Business Strategy

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

More from In Vivo